Literature DB >> 2256525

Inhibition of oral contraceptive steroid-metabolizing enzymes by steroids and drugs.

F P Guengerich1.   

Abstract

The major 17 alpha-ethinyl estradiol 2-hydroxylase is humans is the hepatic enzyme cytochrome P-450 IIIA4 (P-450NF), which is known to be inducible by rifampicin or barbiturates. The literature indicates that 17 beta-estradiol, progesterone, and norgestrel are competitive inhibitors and that primaquine and tolbutamide are rather weak noncompetitive inhibitors. Recent experiments in this laboratory indicate that gestodene is a relatively potent mechanism-based inactivator of cytochrome P-450 IIIA4 in vitro. Inhibition requires incubation with the reduced form of nicotinamide adenine dinucleotide phosphate, is time and concentration dependent, and can be partially blocked by the presence of noninhibitory cytochrome P-450 IIIA4 substrates. The in vitro activation by gestodene provides a possible explanation for the increase in plasma estrogen levels reported in women administered gestodene along with 17 alpha-ethinyl estradiol.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2256525     DOI: 10.1016/0002-9378(90)90557-n

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  19 in total

Review 1.  Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2021-01-18       Impact factor: 5.153

Review 2.  Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation.

Authors:  P Glue; C R Banfield; J L Perhach; G G Mather; J K Racha; R H Levy
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

Review 3.  Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug.

Authors:  Hongjian Zhang; Donghui Cui; Bonnie Wang; Yong-Hae Han; Praveen Balimane; Zheng Yang; Michael Sinz; A David Rodrigues
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 4.  [Differences between men and women in side effects of second-generation antipsychotics].

Authors:  W Aichhorn; A B Whitworth; E M Weiss; H Hinterhuber; J Marksteiner
Journal:  Nervenarzt       Date:  2007-01       Impact factor: 1.214

Review 5.  Clinical pharmacokinetic considerations in the elderly. An update.

Authors:  M T Kinirons; P Crome
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

Review 6.  Formation and Cleavage of C-C Bonds by Enzymatic Oxidation-Reduction Reactions.

Authors:  F Peter Guengerich; Francis K Yoshimoto
Journal:  Chem Rev       Date:  2018-06-22       Impact factor: 60.622

7.  Antibiotic and oral contraceptive drug interactions: Is there a need for concern?

Authors:  G G Zhanel; S Siemens; K Slayter; L Mandell
Journal:  Can J Infect Dis       Date:  1999-11

8.  Influence of ethinylestradiol-containing combination oral contraceptives with gestodene or levonorgestrel on caffeine elimination.

Authors:  A Balogh; G Klinger; L Henschel; A Börner; R Vollanth; W Kuhnz
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 9.  Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations.

Authors:  M I Wilde; J A Balfour
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

Review 10.  Gender effects in pharmacokinetics and pharmacodynamics.

Authors:  R Z Harris; L Z Benet; J B Schwartz
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.